RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
Rhea-AI Summary
RenovoRx (Nasdaq: RNXT) announced that a pharmacokinetic and pharmacodynamic sub‑study from its Phase III TIGeR‑PaC trial was accepted for presentation at the 2026 ASCO Annual Meeting.
The abstract (E16463) compares intra‑arterial gemcitabine via RenovoCath (IAG) with IV gemcitabine, examining systemic drug/metabolite levels and correlation with CA 19‑9. Online publication is scheduled for May 21, 2026 at 5:00 PM ET, and the meeting runs May 29–June 2, 2026 in Chicago.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RNXT
On the day this news was published, RNXT declined 5.09%, reflecting a notable negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $38.59M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data show RNXT moving up while tracked peer TPST is down 4.31%. Other biotech peers show mixed single‑stock moves, suggesting this ASCO abstract news is being treated as stock‑specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Clinical data update | Positive | +1.0% | Imaging data from TIGeR‑PaC showing localized intra-arterial gemcitabine delivery. |
| Apr 08 | IP / patent news | Positive | +4.3% | Japanese patent allowance strengthening RenovoCath and TAMP platform protection. |
| Apr 01 | Corporate recognition | Positive | -4.0% | Named to Fast Company’s 2026 Most Innovative Companies list in medical devices. |
| Mar 30 | Earnings and update | Negative | -5.6% | 2025 results showing higher revenue but a wider net loss and cash update. |
| Mar 26 | Clinical trial milestone | Positive | +5.5% | TIGeR‑PaC enrollment surpassing 100 randomized patients toward final targets. |
RNXT has mostly traded in line with news flow, with four aligned reactions and one divergence where shares fell on otherwise positive recognition news.
Over recent months, RNXT has highlighted progress around its TAMP™ platform and RenovoCath. Clinical imaging data and enrollment milestones in the Phase III TIGeR‑PaC trial (e.g., surpassing 100 randomized patients and targeting 114 randomizations and 86 events) have generally coincided with positive price reactions. Corporate developments such as patent expansion in Japan and recognition by Fast Company were also disclosed, alongside 2025 results showing $1.1 million in RenovoCath revenue and a March 2026 private placement. Today’s ASCO‑focused PK/PD abstract fits this ongoing clinical-validation narrative.
Regulatory & Risk Context
An effective S-3 shelf dated 2026-04-16 registers up to 8,438,790 common shares, 2,200,000 pre-funded-warrant shares, and 5,319,392 milestone-warrant shares for resale from a March 2026 private placement. The company will not receive proceeds from resales but may receive up to $9.3 million if all Milestone Warrants are exercised for cash.
Market Pulse Summary
The stock moved -5.1% in the session following this news. A negative reaction despite supportive PK/PD data would fit past instances where favorable corporate news did not translate into sustained gains, such as the Fast Company recognition. The ASCO abstract adds to a stream of clinical and trial updates, while an S-3 registration is in place for resale of prior financing shares. Weakness following good news could reflect concerns about financing overhangs or the time remaining until full Phase III data.
Key Terms
pharmacokinetic medical
pharmacodynamic medical
tamp™ therapy platform medical
intra-arterial medical
gemcitabine medical
ca 19-9 medical
biomarker medical
locally advanced pancreatic cancer medical
AI-generated analysis. Not financial advice.
Accepted Abstract is a Sub-Study in RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP™ Therapy Platform’s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of Chemotherapy
MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
The abstract, entitled “The TIGeR-PaC Phase 3 III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study,” explores RenovoRx’s lead product candidate, intra-arterial delivery of gemcitabine via RenovoCath (known as IAG), and its potential to reduce systemic levels of the chemotherapy gemcitabine and increase levels of its inactive metabolite compared with intravenous gemcitabine. Additionally, the abstract studies IAG administration and its direct correlation between the metabolite levels and CA 19-9, a biomarker commonly used to assess potential chemotherapy response.
“This study provides important insights into how targeted intra-arterial delivery of chemotherapy may optimize drug distribution and pharmacologic activity in locally advanced pancreatic cancer,” said Dr. Ramtin Agah, RenovoRx’s Executive Chairman and Chief Medical Officer, and study co-author. “We believe IAG has the potential to enhance effectiveness of therapeutic delivery while reducing systemic toxicity and common side effects.”
The 2026 ASCO Annual Meeting will be held May 29 – June 2, 2026, in Chicago, Illinois, with the online publication of the abstract scheduled for May 21, 2026, at 5:00 P.M. ET.
Abstract Details:
Online Publication Date & Time: May 21, 2026, at 5:00 P.M. ET
Number for Publication: E16463
Title: The TIGeR-PaC Phase III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study.
About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In its first full year of commercial efforts, RenovoRx generated approximately
RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the anticipated benefits to the Company of the clinical study abstract described herein, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to commercialize RenovoCath and our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations, strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our commercial sales efforts for RenovoCath and our TAMP technology may not lead to viable, revenue-generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of our preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRx@KCSA.com
Media Contact:
STiR Communications
Hannah Williams
T: 803-521-1214
hannah@stir-communications.com
